KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Notes Payables (2023 - 2025)

Bionano Genomics' Notes Payables history spans 3 years, with the latest figure at $9.8 million for Q3 2025.

  • For Q3 2025, Notes Payables fell 34.29% year-over-year to $9.8 million; the TTM value through Sep 2025 reached $9.8 million, down 34.29%, while the annual FY2024 figure was $20.4 million, 70.83% down from the prior year.
  • Notes Payables for Q3 2025 was $9.8 million at Bionano Genomics, down from $11.8 million in the prior quarter.
  • Across five years, Notes Payables topped out at $69.8 million in Q4 2023 and bottomed at $9.8 million in Q3 2025.
  • The 3-year median for Notes Payables is $17.2 million (2024), against an average of $23.5 million.
  • The largest annual shift saw Notes Payables crashed 70.83% in 2024 before it crashed 34.29% in 2025.
  • A 3-year view of Notes Payables shows it stood at $69.8 million in 2023, then plummeted by 70.83% to $20.4 million in 2024, then tumbled by 51.75% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Notes Payables are $9.8 million (Q3 2025), $11.8 million (Q2 2025), and $13.0 million (Q1 2025).